The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys

By Skiadopoulos M.H.   Tatem J.M.   Surman S.R.   Mitcho Y.   Wu S.-L.   Elkins W.R.   Murphy B.R.  

Vaccine, Vol. 20, Iss. 13, 2002-03 ,pp. : 1846-1852

Elsevier

Access to resources Recommend Favorite

African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection

By Durbin A.P.   Elkins W.R.   Murphy B.R.  

Vaccine, Vol. 18, Iss. 22, 2000-05 ,pp. : 2462-2469

Elsevier

Access to resources Recommend Favorite

Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection

By de Martino M.   Podda A.   Galli L.   Sinangil F.   Mannelli F.   Rossi M.E.   Vierucci A.  

Vaccine, Vol. 15, Iss. 11, 1997-08 ,pp. : 1235-1238

Elsevier

Access to resources Recommend Favorite

Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates

By Jin H.   Cheng X.   Traina-Dorge V.L.   Park H.J.   Zhou H.   Soike K.   Kemble G.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3647-3652

Elsevier

Access to resources Recommend Favorite

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

By Wyatt L.S.   Shors S.T.   Murphy B.R.   Moss B.  

Vaccine, Vol. 14, Iss. 15, 1996-10 ,pp. : 1451-1458

Elsevier

Access to resources Recommend Favorite